[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypermobile-ehlers-danlos-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypermobile-ehlers-danlos-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642514","presentation-of-young-adults-with-and-without-joint-hypermobility-100642514",false,"NCT07657507","Presentation of Young Adults With and Without Joint Hypermobility","Prospective Study of Symptoms in People With and Without Joint Hypermobility","Inclusion Criteria: Clarkson University Health Sciences students. -\n\nExclusion Criteria: Other physical conditions that preclude collecting \\>25% of physical measurements at initial data collection.\n\n\\-",true,"ALL","18 Years","60 Years",{"count":21,"type":22},100,"ESTIMATED","5 Years","OBSERVATIONAL","People with multiple hypermobile joints are diagnosed with Generalized Joint Hypermobility (GJH) when asymptomatic, or Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) when symptomatic (hEDS\u002FHSD, or 'HSD' here). GJH likely affects about 20% of the U.S. population, while HSD affects 0.5-3% of the US population. Although joint hypermobility is the most visible presentation of HSD, it is a systemic connective tissue disorder affecting multiple body systems. Due to frequent health concerns, HSD may contribute to more than 30% of patients in chronic pain, rheumatology, orthopedic and physical therapy clinics. It is still unclear why some people have asymptomatic hypermobility and others develop complex chronic health issues. However, recent research suggests that the transition might be triggered by severe physiological stress, such as viral infection.\n\nHSD is commonly associated with Postural Orthostatic Tachycardia Syndrome (POTS) and Mast Cell Activation Syndrome (MCAS), as well as gastrointestinal (GI) problems. Recent research suggests that persistent inflammation due to MCAS or COVID may trigger HSD symptoms. The correlation between POTS and HSD may be due to effects of HSD on the autonomic nervous system or to inflammation triggering both conditions. It is also unclear whether body awareness and coordination deficits seen in symptomatic HSD are due to the fundamental connective tissue disorder or due to pain and injuries in HSD. This study seeks to determine whether asymptomatic hypermobile individuals (GJH) also have balance and coordination deficits. The current study hopes to identify factors that correlate with a transition from asymptomatic GJH to symptomatic HSD by following a group of Health Science students forward in time. The study will collect baseline health information including relevant diagnoses, symptoms and function. Physical measurements will include standard clinical tests performed by physical therapists: joint hypermobility and instability, standing balance, neck movement control, and heart rate in response to standing from lying down. The study is likely to last for at least 10 years to follow participants over time.",[27,28],"Hypermobile Ehlers-Danlos Syndrome","Postural Orthostatic Tachycardia Syndrome (POTS)",[30,31,32],"hypermobile Ehlers-Danlos Syndrome","Hypermobility Spectrum Disorders","Risk factors","NOT_YET_RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":22},"2026-06-20",{"date":41,"type":22},"2036-06-20",{"name":43,"class":44},"Clarkson University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":45},"100639329","hamstring-strengthening-in-hypermobile-conditions-100639329","NCT07626957","Hamstring Strengthening in Hypermobile Conditions","Effects and Feasibility of Eccentric Hamstring Strengthening in Hypermobility Spectrum Disorders and Hypermobile Ehlers-Danlos Syndrome","Inclusion Criteria:\n\n* Reported diagnosis of HSD or hEDS by a physician\n* Meet the 2017 International Diagnostic Criteria for HSD and hEDS\n* Clearance to participant in exercise participation, determined using the Get Active Questionnaire\n\nExclusion Criteria:\n\n* Other acquired or hereditary connective tissue disorder (i.e., rheumatoid arthritis, Marfan syndrome, etc.)\n* Currently experiencing daily knee pain\n* Prior knee injury or surgery\n* Intra-articular knee injection in the last 12 months\n* Currently pregnant","FEMALE","55 Years",{"count":56,"type":22},20,"INTERVENTIONAL",[59],"NA","The goal of this clinical trial is to determine how strengthening the hamstring muscles affects the knee joint in people living with hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS). The main questions it aims to answer are:\n\n* Does hamstring strengthening reduce the looseness of the knee joint in HSD\u002FhEDS?\n* Does hamstring strengthening improve clinical outcomes like pain in people living with HSD\u002FhEDS?\n\nParticipants will:\n\n* Attend two exercise classes per week for 12 weeks.\n* Visit the laboratory every 4-6 weeks for testing.",[62,27,63,64],"Hypermobile EDS (hEDS)","Hypermobile Spectrum Disorder","Hypermobility Type Ehlers-Danlos Syndrome",[66,67,68,69,70,71,72,27,31,73,74],"Exercise","Female","Knee","Joint Laxity","Hypermobility","Joint Stiffness","Ehlers-Danlos Syndrome","strengthening","eccentric","2026-05-29",{"date":77,"type":37},"2026-06-04",{"date":79,"type":22},"2026-06-01",{"date":81,"type":22},"2027-08-01",{"name":83,"class":44},"University of Calgary",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":18,"enrollmentInfo":92,"targetDuration":4,"studyType":57,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100455558","auricular-vagal-nerve-stimulation-for-hypermobile-ehlers-danlos-syndrome-100455558","NCT05212129","Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome","Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology","Inclusion Criteria:\n\n* Children aged 10-18 years old\n* Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4\u002F9\n* Children with functional upper GI complaints and clinical suspicion for ANS dysfunction\n* De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group\n* Children who are English-speaking and lack other explanation for symptoms\n* Children willing to participate and consent to this study (for children, have a parent willing to participate)\n\nExclusion Criteria:\n\nA) Exclusion Criteria applying to all participants:\n\n* Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study.\n* Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)\n* Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study.\n* Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded.\n* Pregnancy (evaluating MD screens patients as they normally would during a clinic visit (by questioning) and would only perform urine pregnancy test if clinically indicated (absence of menstrual period or other symptoms concerning for pregnancy)\n* Chronic alcohol\u002Fillicit drug use and\u002For smoking.\n\nB) Exclusion Criteria for subjects undergoing pVNS therapy:\n\n* Severe dermatological condition or active infection of external or middle ear\n* Implanted electrical device\n\nC) Exclusion Criteria for subjects undergoing aVNS therapy:\n\n* Hearing impaired\n* Sight impaired without correction\n* Seizure disorder\n\nD) Exclusion Criteria for subjects undergoing gastric motor function sub-study:\n\n* Patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with MRI scanning\n* Claustrophobia or inability to lie still in the scanner\n* Orthodontic braces or permanent retainers\n* Patients who are unable to tolerate noise produced by the MRI\n* Egg allergy or anticipated inability to complete a standardized egg meal\n\nE) Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:\n\n* Bleeding disorder for the specific biopsies\n* Recent antibiotic usage for fecal sample\n* Significant anemia or clinical status which will not allow safe blood draw required for blood collection\n* Refusal of blood collection or to provide DNA sample\n* Inability or unwillingness on the individual (or parent\u002Flegal guardian) to provide clinical or family history.","10 Years",{"count":93,"type":22},90,[59],"Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS\u002FHypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.",[97,27,98,99,100],"Functional Gastrointestinal Disorders","Postural Orthostatic Tachycardia Syndrome","Autonomic Nervous System Disease","Autonomic Nervous System Imbalance","RECRUITING","2026-02-11",{"date":104,"type":37},"2026-02-13",{"date":106,"type":37},"2021-04-05",{"date":108,"type":22},"2026-12-31",{"name":110,"class":44},"Medical College of Wisconsin"]